Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Investigating the in utero toxicity of Anti-HIV drugs across Placental-Fetal Barriers

FY 2024-25

Summary
The use of HIV medications has proven effective for treating HIV in pregnancy and has significantly lessened the rates of mother-to-child HIV transmission. However, the number of babies who are HIV-exposed but uninfected (CHEU) continues to increase, along with a subsequent rise in some negative birth outcomes such as being born smaller than expected or having birth defects. The underlying reasons for these issues and the long-term effects of antiretroviral therapy on CHEU are not well understood; however, it is likely related to how much drug is transferred from the mother to the fetus. Drug transporter proteins and metabolic enzymes found on the placenta play a critical role in regulating the transfer and/or degradation of drugs from maternal to fetal circulation and have expression patterns that change throughout pregnancy. Additionally, sex has also been identified as playing a role in the expression levels of various drug transporters and enzymes in adult humans and rodents, but if this happens in the fetus is unknown. This project aims to study how the expression and localization of specific drug transporters and metabolic enzymes change across gestation and ultimately affect the transfer of HIV medications across human and rodent placentas. Drug transporter and metabolic enzyme expression and localization, as well as HIV medication levels, will be compared between female and male fetuses to assess potential fetal toxicities and sex differences. I will focus on newer HIV medications such as dolutegravir, bictegravir, and cabotegravir and use various placenta cells, explants, and animal models that mimic the different stages of pregnancy to investigate the objectives. Overall, this study will provide novel information on the changes in drug transporter and metabolic enzyme expression across gestation, which is a critical component of fetal drug transfer/degradation and potential fetal drug toxicities associated with HIV medication during pregnancy.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
518289
Name
Bennett Teresa M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the in utero toxicity of Anti-HIV drugs across Placental-Fetal Barriers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antiretroviral Drugs; Drug Transporters And Metabolic Enzymes; Fetal Health; Folate Deficiency; Hiv; In Utero Toxicities; Neural Tube Defects; Placenta; Preterm Birth
Abstract
The use of HIV medications has proven effective for treating HIV in pregnancy and has significantly lessened the rates of mother-to-child HIV transmission. However, the number of babies who are HIV-exposed but uninfected (CHEU) continues to increase, along with a subsequent rise in some negative birth outcomes such as being born smaller than expected or having birth defects. The underlying reasons for these issues and the long-term effects of antiretroviral therapy on CHEU are not well understood; however, it is likely related to how much drug is transferred from the mother to the fetus. Drug transporter proteins and metabolic enzymes found on the placenta play a critical role in regulating the transfer and/or degradation of drugs from maternal to fetal circulation and have expression patterns that change throughout pregnancy. Additionally, sex has also been identified as playing a role in the expression levels of various drug transporters and enzymes in adult humans and rodents, but if this happens in the fetus is unknown. This project aims to study how the expression and localization of specific drug transporters and metabolic enzymes change across gestation and ultimately affect the transfer of HIV medications across human and rodent placentas. Drug transporter and metabolic enzyme expression and localization, as well as HIV medication levels, will be compared between female and male fetuses to assess potential fetal toxicities and sex differences. I will focus on newer HIV medications such as dolutegravir, bictegravir, and cabotegravir and use various placenta cells, explants, and animal models that mimic the different stages of pregnancy to investigate the objectives. Overall, this study will provide novel information on the changes in drug transporter and metabolic enzyme expression across gestation, which is a critical component of fetal drug transfer/degradation and potential fetal drug toxicities associated with HIV medication during pregnancy.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bennett, Teresa M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~